Summary:
- Bridge Bio, a biopharmaceutical company, has reported its financial results for the second quarter of 2025.
- The company's pipeline includes several drug candidates in various stages of development, focusing on rare and genetic diseases.
- The report highlights the progress made in the company's research and development efforts, as well as its financial position and plans for the future.